Iran Develops Radiopharmaceutical for Cancer Treatment


Iran Develops Radiopharmaceutical for Cancer Treatment

TEHRAN (Tasnim) – A research center of the Atomic Energy Organization of Iran (AEOI) has produced a radiopharmaceutical used for the treatment of cancerous tumors.

Scientists at the AEOI’s Nuclear Science and Technologies Research Center have developed the Rhenium-188-based radiopharmaceutical for the treatment of neuroendocrine tumors (NETs).

The new drug containing radioactive isotopes, named 188Re-TOC, is recognized as a promising radiopharmaceutical for diagnosing and curing neuroendocrine tumors.

Iranian experts in the pharmaceutical industry have in recent years made great headways in producing medicines used to cure a broad range of diseases.

The Nuclear Science and Technologies Research Center of Iran has already produced dozens of radiopharmaceuticals for diagnostic and therapeutic procedures and for research and development.

Top Nuclear stories
Top Stories